Kalantar Arash, Rezaei Mahya, Jafarzadeh Kohneloo Aarefeh, Taghizadeh-Ghehi Maryam
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran.
Int J Clin Pharm. 2023 Apr;45(2):397-405. doi: 10.1007/s11096-022-01518-0. Epub 2022 Dec 5.
Opioid analgesics play a unique role in pain management. National opioid consumption studies could provide indirect evidence of pain management in a country. National, regional, and global opioid consumption have been studied in other countries so far; however, conducting a focused study to illuminate the consumption of opioid analgesics over the past decades in Iran seemed necessary.
The main objective of this study was to determine the consumption of opioid analgesics and explore the trend of their use during 19 years in Iran.
Iran pharmaceutical wholesale data were used to extract the annual consumption figures of the opioid analgesics in group N02A of the World Health Organization (WHO) Anatomical Therapeutic Chemical classification and were available in Iran (morphine, fentanyl, pethidine, and oxycodone as strong opioids and, tramadol and pentazocine as weak opioids), from 2000 to 2018. Using Defined Daily Dose (DDD) by WHO and Oral Morphine Equivalent (OMEQ), the amount of annual consumption was determined in DDD/1000 inhabitants/Day (DID) and OMEQ (mg)/1000 inhabitants/Day (OID).
Total opioid analgesic utilization based on DID and OID increased 31.12-fold (from 0.0196 to 0.61) and 21.06-fold (from 1.97 to 41.5 mg) over 19 years, respectively with a significant sharp increase from 2003 to 2006 (ß = 1.78 (DID), P value < 0.001). Medications that constituted 70% of annual opioid analgesics utilization were morphine in 2000, compared to tramadol in 2018. The annual weak and strong opioids share were 86.7% and 13.2% in 2018, respectively.
Despite considerable growth in the consumption of opioid analgesics in Iran over nearly two decades, the consumption amount remained low, which might signal sub-optimal pain management. On the other hand, misuse and abuse seem to be the main reason behind significant increases in the consumption of opioid analgesics with less controlled distribution.
阿片类镇痛药在疼痛管理中发挥着独特作用。全国阿片类药物消费研究可为一个国家的疼痛管理提供间接证据。到目前为止,其他国家已经对全国、区域和全球的阿片类药物消费情况进行了研究;然而,开展一项针对性研究以阐明伊朗过去几十年阿片类镇痛药的消费情况似乎很有必要。
本研究的主要目的是确定伊朗阿片类镇痛药的消费量,并探讨其在19年中的使用趋势。
利用伊朗药品批发数据,提取世界卫生组织(WHO)解剖治疗化学分类中N02A组阿片类镇痛药在伊朗的年消费数据(吗啡、芬太尼、哌替啶和羟考酮作为强阿片类药物,曲马多和喷他佐辛作为弱阿片类药物),时间跨度为2000年至2018年。使用WHO定义的每日剂量(DDD)和口服吗啡当量(OMEQ),以DDD/1000居民/天(DID)和OMEQ(mg)/1000居民/天(OID)来确定年消费量。
基于DID和OID的阿片类镇痛药总消费量在19年中分别增长了31.12倍(从0.0196增至0.61)和21.06倍(从1.97增至41.5mg),2003年至2006年有显著的急剧增加(β = 1.78(DID),P值<0.001)。2000年占阿片类镇痛药年消费量70%的药物是吗啡,而2018年是曲马多。2018年,弱阿片类药物和强阿片类药物的年占比分别为86.7%和13.2%。
尽管近二十年来伊朗阿片类镇痛药的消费量有显著增长,但消费量仍然较低,这可能表明疼痛管理未达最佳水平。另一方面,滥用似乎是阿片类镇痛药消费量在分销管控不力情况下大幅增加的主要原因。